Survival following initiation of everolimus for second-line treatment of metastatic renal cell carcinoma: Prognostic factors in clinical practice and comparison to clinical trials.
Publication
, Conference
Wong, MKK; Jonasch, E; Pal, SK; Signorovitch, JE; Lin, PL; Liu, Z; Wang, X; Culver, KW; Scott, JA; George, DJ; Vogelzang, NJ
Published in: JOURNAL OF CLINICAL ONCOLOGY
2013
Duke Scholars
Published In
JOURNAL OF CLINICAL ONCOLOGY
EISSN
1527-7755
ISSN
0732-183X
Publication Date
2013
Volume
31
Issue
15
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis
- 1103 Clinical Sciences
Citation
APA
Chicago
ICMJE
MLA
NLM
Wong, M. K. K., Jonasch, E., Pal, S. K., Signorovitch, J. E., Lin, P. L., Liu, Z., … Vogelzang, N. J. (2013). Survival following initiation of everolimus for second-line treatment of metastatic renal cell carcinoma: Prognostic factors in clinical practice and comparison to clinical trials. In JOURNAL OF CLINICAL ONCOLOGY (Vol. 31).
Wong, Michael K. K., Eric Jonasch, Sumanta Kumar Pal, James E. Signorovitch, Peggy L. Lin, Zhimei Liu, Xufang Wang, et al. “Survival following initiation of everolimus for second-line treatment of metastatic renal cell carcinoma: Prognostic factors in clinical practice and comparison to clinical trials.” In JOURNAL OF CLINICAL ONCOLOGY, Vol. 31, 2013.
Wong MKK, Jonasch E, Pal SK, Signorovitch JE, Lin PL, Liu Z, et al. Survival following initiation of everolimus for second-line treatment of metastatic renal cell carcinoma: Prognostic factors in clinical practice and comparison to clinical trials. In: JOURNAL OF CLINICAL ONCOLOGY. 2013.
Wong, Michael K. K., et al. “Survival following initiation of everolimus for second-line treatment of metastatic renal cell carcinoma: Prognostic factors in clinical practice and comparison to clinical trials.” JOURNAL OF CLINICAL ONCOLOGY, vol. 31, no. 15, 2013.
Wong MKK, Jonasch E, Pal SK, Signorovitch JE, Lin PL, Liu Z, Wang X, Culver KW, Scott JA, George DJ, Vogelzang NJ. Survival following initiation of everolimus for second-line treatment of metastatic renal cell carcinoma: Prognostic factors in clinical practice and comparison to clinical trials. JOURNAL OF CLINICAL ONCOLOGY. 2013.
Published In
JOURNAL OF CLINICAL ONCOLOGY
EISSN
1527-7755
ISSN
0732-183X
Publication Date
2013
Volume
31
Issue
15
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 1112 Oncology and Carcinogenesis
- 1103 Clinical Sciences